Related Experiment Video
Updated: Jul 6, 2026
07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
[Homocysteine and rheumatic disease].
Ilaria Tinazzi1, Paola Caramaschi, Giuseppe Patuzzo
1Dipartimento di Medicina Clinica e Sperimentale, Università, Verona.
Recenti Progressi in Medicina
|March 29, 2008
Summary
High homocysteine levels are a risk factor for blood clots and may worsen vascular damage in rheumatic diseases. This may explain increased cardiovascular events not linked to traditional risk factors.
Area of Science:
- Cardiovascular Science
- Rheumatology
- Metabolic Disorders
Background:
- Hyperhomocysteinemia is an emerging risk factor for atherothrombosis.
- A potential role for hyperhomocysteinemia in rheumatic diseases has been proposed.
- This condition may amplify vascular damage in rheumatic patients.
Purpose of the Study:
- To investigate the role of hyperhomocysteinemia in rheumatic diseases.
- To explore the interaction between hyperhomocysteinemia and treatments for rheumatic conditions.
- To understand the contribution of hyperhomocysteinemia to cardiovascular events in rheumatic diseases.
Main Methods:
- Literature review on hyperhomocysteinemia and rheumatic diseases.
- Analysis of existing data on cardiovascular event incidence in rheumatic patients.
- Correlation studies between homocysteine levels and vascular damage markers.
Main Results:
- Hyperhomocysteinemia is a significant risk factor for atherothrombosis.
- Evidence suggests hyperhomocysteinemia exacerbates vascular damage in rheumatic diseases.
- This condition may influence treatment efficacy and outcomes.
Conclusions:
- Hyperhomocysteinemia is a critical factor in atherothrombosis and rheumatic disease progression.
- Managing homocysteine levels could be crucial for reducing cardiovascular risk in rheumatic patients.
- Further research is warranted to elucidate the mechanisms and therapeutic implications.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
01:20Rheumatic Heart Disease IV: Nursing Management
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:22Connective Tissue Cell Types
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...